Report Date: 2026-11-15 | Research Subject: Civilian Uranium Enrichment Services (industry slug: uranium-enrichment-services) | Analytical Framework: Generic Value Chain | Industry View: Cautiously Bullish (12–24 months)
Core conclusion: Uranium enrichment is currently the link with the strongest pricing power and most concentrated profit pool in the front end of the nuclear fuel chain. Western markets (US/EU/Korea/Japan) face an institutional supply gap of roughly 11.9 million SWU (MSWU)/year under artificially segmented policy, persisting to around 2030; spot at USD 200/SWU sits at the 100th percentile of the past 16 years, while the US long-term contract realized price is only USD 108.70 — repricing plus pipeline protection imply profit upside for incumbents over the next 3–5 years. But we must be clear-eyed: all three legs of the gap (US waiver, no EU embargo, overfeeding flexibility) are policy and contract variables, not physical capacity variables; DOE-subsidized capacity, Urenco/Orano expansions, and GLE laser technology all ramping in 2029–2032 carry isomorphic risk with the historical 2010–2016 cycle template (spot 160→34 USD). Cautiously bullish, with close attention to the January 2028 US full Russia ban node — that is this report's stance.
Uranium enrichment services are the third link in the front end of the nuclear fuel cycle: natural uranium (U3O8, mine output) → conversion to uranium hexafluoride (UF6) → enrichment to 3–5% low-enriched uranium (LEU, fuel for civilian power reactors) or 5–20% HALEU (advanced reactor fuel) → fuel fabrication. This report's research subject is only the enrichment link — services metered and priced in Separative Work Units (SWU), which constitute a market with independent pricing, competitive dynamics, and market structure from upstream uranium mining (U3O8, priced in USD/lb) and conversion (UF6, priced in USD/kgU). Confusing the three is a common error: in this cycle, the enrichment price increase (spot +233% vs the 2020 trough) far exceeds uranium mining (US realized price +11.3% in 2025 to USD 58.46/lb); the commercial logic of the three links is not isomorphic.
One-sentence value chain map: Mining (Kazatomprom/Cameco/Orano mining) → Conversion (ConverDyn/Orano/Cameco Port Hope/Rosatom) → Enrichment (Urenco/Orano/TENEX/Centrus/CNNC) → Fabrication (Westinghouse/Framatome/GEH/CNNC) → Utilities. Global nominal enrichment capacity is about 68.1 MSWU/year (2025, WNA), shared among five players with CR3 at 88.5% — a classic oligopolistic service market: no exchange futures, prices formed mainly through 5–15 year long-term contracts, with spot serving only marginal price discovery. This industry is analyzed under the generic value chain framework.
Global SWU demand in 2025 is about 54.5 MSWU/year (midpoint of the WNA 53–56 range), corresponding to about 400 GWe of operating nuclear capacity (1 GWe LWR annual reload ≈ 140,000 SWU). By region: China ~24%, US ~23%, Europe ~22%, Russian sphere (Russia + CIS + Russian-built export reactors) ~8%, other Asia ~13%. The bottom-up demand bridge shows net growth of +6.9 MSWU from 2025→2030 to 61.4 MSWU:
Of the demand bridge's net increase of 6.9 MSWU, China contributes +6.6 (96%), and China is fully self-sufficient via CNNC capacity (13.8→18.2 MSWU, WNA estimate; IPFM satellite evidence suggests ~14.4 MSWU after two new plants start up in 2026–27) — global apparent demand growth circulates within China's self-sufficient closed loop. Western regional demand (36.9 MSWU, 2025) has organic net growth of only ~1.1 MSWU over 2025–2032; its true marginal driver is policy-driven demand to replace Russian supply: in 2025, Russian supply still accounts for 26% of US purchases (3.284 MSWU, EIA, all imported under DOE waivers), and Russian supply is 22.55% of EU deliveries (2,735 tSW, ESA) — after the US waiver expires in January 2028 this portion must shift to Western capacity, and EU VVER operators have all locked in non-Russian replacement contracts by end-2025. In other words, Western enrichers' boom comes not from demand prosperity, but from geopolitical repricing.
Structural forces: ① China's 35 reactors under construction coming online one by one (+5–8 GW/year); ② institutional transfer away from Russia (US ban Aug 2024, UK ban May 2026, full US prohibition Jan 2028); ③ AI data center 20-year nuclear PPAs (Microsoft–Crane 835 MW, Microsoft–Clinton 1.1 GW, etc.) locking existing reactor lifetimes into the 2040s — note their pass-through to SWU is only ~0.2–0.3 MSWU in absolute terms; the effect is "preventing de-rating + locking tenor," not increment. Cyclical forces: ① utility inventory cadence (US 2025 purchases -16.2% to 12.7 MSWU, a digestion year after 2022–24 stockpiling, though realized prices still +11.3%); ② the technical flexibility of overfeeding/underfeeding — raising tails assay from 0.22% to 0.25% saves 6.3% of SWU (costing 5.8% more natural uranium), and to 0.30% saves 15.1% (costing 17.2% more), so nominal demand can swing within ±6–15%. SMR/HALEU increment before 2030 is only ~0.8 MSWU (1.5%; first-of-a-kind delays could zero it out) — a high-premium option, not current profit. HALEU uses ~41 SWU/kg, 5.6x that of LEU, but total volume before 2030 is limited.
Global nominal capacity in 2025 is 68.076 MSWU/year (WNA, updated 2026-10): Rosatom/TENEX 29.133 (42.8%, four plants + GC-9+/10th-generation centrifuge upgrades underway), Urenco 17.3 (25.4%, four plants in UK/Netherlands/Germany/US), CNNC 13.789 (20.3%), Orano 7.5 (11.0%), JNFL and others ~0.5. Global nominal surplus is ~25%, but the market is policy-cut into two regions: Russian and Chinese capacity totaling 63% does not serve the West; Western effective capacity is only 24.95 MSWU/year (Urenco 17.3 + Orano 7.5 + JNFL 0.15) against addressable demand of 36.9–37.6, a gap of ~11.9 MSWU/year. Western plants are effectively at full load, creating headroom by raising tails (0.25–0.30%) — note that at current relative prices this is a loss-making fulfillment behavior of "consuming natural uranium to buy SWU" (roughly USD 129 pure loss per kg EUP; breakeven SWU price ~USD 317), which precisely proves the tightness is a physical bottleneck, not a price equilibrium.
Western announced expansions total roughly 15.5–18 MSWU of nominal capacity, but the timing distribution is extremely uneven:
| Project | Operator | New Capacity | Startup | Status |
|---|---|---|---|---|
| Eunice Phase 1 | Urenco | +0.7 MSWU | First cascade May 2025 → completion 2027 | Under construction (6/8 as of 2026-10) |
| Almelo Phases 1/2 | Urenco | +1.5 MSWU | 2027 / 2030 | Under construction + FID |
| Eunice Phase 2 | Urenco | +2.1 MSWU | Ground broken Aug 2026, first production 2032/full 2036 | FID (multi-billion-dollar scale) |
| GBII expansion | Orano | +2.5 MSWU (7.5→10) | First module 2028/full 2030 | Under construction (EUR 1.7bn, EUR 400m EIB loan) |
| Project Ike | Orano | ≤7.4 MSWU | Groundbreaking planned Sep 2027, first production Jan 2032/full 2039 | Under NRC review (DOE USD 900m) |
| Piketon HALEU | Centrus | 12 t HALEU/year (≈0.49 MSWU equivalent) | 2029 | Under construction (DOE USD 900m) |
| Paducah PLEF | GLE (Silex 51%/Cameco 49%) | Not disclosed (early estimates 0.5–1.0) | FEIS cleared (2026-10-28), licensing target early 2027, production target 2030 | In approval, Cameco 100% exclusive offtake |
| Paducah greenfield | General Matter | Target 1.5 MSWU | Around 2032 | NRC application Sep 2026 (DOE USD 900m) |
Real deployment in 2026–2028 is only ~2.1 MSWU, while 2029–2032 committed additions are ~7.5 MSWU (plus full Eunice Phase 2 and Ike ramp post-2032) — supply's "near drought, far flood" is precisely the shape of this industry's cycle:
Lags and chokepoints: brownfield (adding cascades at existing sites) FID→first production 2–4 years, full capacity 5–10 years; greenfield (Ike/GLE/GM) licensing→first production 5–8 years. The key chokepoint is not power (40–50 kWh/SWU) but: ① NRC queue of three parallel reviews (Ike has already been delayed past its April 2027 target by supplemental filings); ② centrifuge manufacturing speed — only ETC (co-owned by Urenco/Orano) self-supplies in the West, and Centrus only shipped the first AC100M of its expansion on 2026-10-31; ③ small items like HALEU-specific cylinders. New-build incentive price is roughly USD 85–100/SWU (greenfield capital intensity of USD 650–1,000/SWU annualized ~USD 63 + opex/power), far below the USD 200 spot — the expansion incentive is extremely strong, and DOE's USD 2.728bn in subsidies is pushing the actual incentive price floor even lower.
① HEU downblending: The US–Russia "Megatons to Megawatts" program has ended (500 t weapons-grade HEU ≈ 90 MSWU over 20 years); remaining military HEU of ~1,500 t is a huge theoretical ceiling but constrained by military retention and blendstock, and realistic annualized increments contribute negligibly to the 2026–2030 gap. ② Depleted uranium re-enrichment: The US holds ~550,000 t of tails (of which the 115,000 t above 0.34% is GLE feedstock; DOE has signed a 300,000 t supply agreement); but at USD 200/SWU, "spending SWU to buy uranium" is uneconomic (breakeven USD 317) — the industry is currently overfeeding in reverse instead. ③ Russian/Chinese redirected supply: All of the US's 26% Russian supply in 2025 was direct imports under waivers; no evidence of third-country re-export was found; Chinese capacity is politically inaccessible to the West (the ADVANCE Act bans Chinese-made fuel in US advanced reactors). Conclusion: alternative pathways will not materially impact the 2026–2029 gap, but GLE laser technology (cheap tails feedstock + new technology + Cameco offtake, three elements) together with DOE-subsidized capacity constitute the biggest upward-revision variable for 2030s supply elasticity — they will determine the depth of the next glut.
Western gap path: -11.9 (2025) → -10.1 (2028, waiver expiry year) → -7.2 (2030) → -3.1 (2032). Disclosure must be in two tiers: nominal gap of 8–11.5 MSWU; after counting overfeeding flexibility (-6~-15% of nominal demand), effective gap of ~5–8 MSWU — the flexibility is real, but its cost is +6~17% demand at the mining and conversion links; the tightness is merely transmitted, not eliminated. The gap is currently bridged by four routes: Russian supply under waiver (US 3.28 MSWU/year), inventories (EU 2025 over-purchase of 3,018 tSW as strategic stockpile ≈ 4 months of core loads), overfeeding, and redirected Russian VVER deliveries. On a global basis, nominal surplus is 20–34% (2032 committed capacity 86.1 vs demand 64.2) — the surplus is in the Russia–China region, the shortage in the Western region, separated by a policy wall. The durability of that wall is this industry's single largest risk variable.
Spot at USD 200/SWU (2025-12 and 2026-06-30, UxC via WNA) is a nominal all-time high, 25% above the 2010 peak; but long-term contract realized prices are the anchor of profit: the US 2025 average realized price of USD 108.70 (+11.3%, EIA) is still 23.6% below the last cycle's realized-price peak (USD 142.22 in 2013). Historical lag structure: spot peaked 2010 → realized price peaked 2013 (+3 years); spot bottomed 2016 → realized price bottomed 2020 (+4 years). Spot reached the USD 193 plateau in late 2024 and has been flat at 200 through 2025–26 — the realized-price repricing pipeline has another 3–5 years; this is both the incumbents' profit reservoir, and it means if spot falls, the profit peak will arrive in 2030–2032, precisely colliding with the new-capacity window (see I7 Controversy D2). Price formation: ~87% of US purchases are via long-term contracts on "base price + inflation escalator + market linkage" formulas; order books stand at Urenco EUR 27.3bn (2026-06-30, +28.2% half-year, ~13x FY2025 revenue), Orano EUR 34.4bn (~6.7x), Centrus USD 3.8bn — incumbents have 95%+ of future deliveries price- and volume-locked into the 2030s. This explains the 2026 divergence between fundamentals and equities: order book +28% half-year vs Centrus stock -62% YTD (-69% from the 2025 high) — the market is discounting not current cash flow, but expectations of a "2028 supply return + spot mean reversion."
Pricing framework: incentive-price floor USD 85–100 + continuing Western regional shortage + order book position (capacity sold out into the 2030s).
| Period | Spot Range (USD/SWU) | US Realized Price (USD/SWU) | Logic |
|---|---|---|---|
| 2026Q4 | 190–210 | 118–126 (2026E) | Gap unresolved, spot consolidating |
| 2027H1 | 180–220 | 125–132 | Reload negotiation season; new LT contract base prices 140–170+ with escalators |
| 2027H2 | 190–250 | 130–145 | Policy brinkmanship before waiver expiry, panic buying intensifies |
| 2027Q4→2028Q1 | No extension: 200–250 / Extension: 170–190 | 130–145 | Decisive reveal period |
CR3 = 88.5% (Rosatom+Urenco+CNNC), HHI ~3,009 — extremely high concentration. But effective competition occurs within the Western region: Urenco:Orano ≈ 70:30, with the US effectively a single commercial supplier before 2032 (Urenco USA). Fivefold barriers: ① centrifuge technology (70,000 rpm rotors, defense-grade classified; even Urenco's shareholder governments cannot access the technology — the root cause of 40 years without new entrants); ② capital (GBII at EUR 680/SWU of capacity; greenfield at USD 5bn scale); ③ licensing (NRC review 5–8 years); ④ customer qualification (fuel design regulatory certification locks in the supply chain); ⑤ geopolitics (123 Agreements/IAEA safeguards). 2025–26 saw the first signs of loosening — General Matter, GLE, and Orano's US plant entering — but all driven by government subsidies (USD 900m each from DOE for the three), itself proof of how high the barriers are.
Front-end four-link profit pool comparison (2025–26 present values): enrichment is currently the most profit-concentrated link with the sharpest price increases — spot +233% vs the 2020 trough; Urenco EBITDA margin 38.4% (FY2025: revenue EUR 2.096bn, EBITDA EUR 804m), operating cash flow EUR 1.047bn > EBITDA, net cash EUR 845m, capex EUR 616m self-funded — a classic cash cow, with sunk costs already paid and price increases falling almost entirely to the bottom line. Uranium mining has the largest nominal revenue pool (~USD 8–9bn/year globally, Kazatomprom EBITDA margin ~63%) but spot has already rolled over from its early-2024 peak; the conversion pool is small and tight (Western effective capacity only 55.6% of global); fabrication profits are internalized within the Westinghouse/GEH/Framatome groups. Migration direction over the next 2–3 years: ① stock LEU scarcity premium migrating toward a "HALEU/LEU+ premium" (Centrus the only HALEU producer; Urenco the first LEU+ certified); ② uranium mining re-claiming share of price gains in the ~2028 LT contract renewal wave (overfeeding transmits SWU tightness into +6~17% mining demand); ③ the payer is utilities (enrichment is only ~5% of electricity cost, so pass-through is smooth) — but note WNA has documented utilities negotiating limits on enrichers' underfeeding gains in new contracts; the sell side's strongest link is being dismantled at the margin by contract terms. Return quality conclusion: this is an extremely profitable business right now (high ROIC, order book at 13x revenue, top-tier cash flow quality); the sustainability of excess returns depends on the policy wall's lifespan and 2030s supply discipline — state shareholders and subsidies are simultaneously eroding the latter.
| Player | Position & Share | Financial Snapshot (FY2025) | One-Line Take |
|---|---|---|---|
| Urenco (unlisted, UK/Netherlands/Germany each 1/3) | Largest Western enricher, 25.4% of global capacity, ~70% of the Western segment; four-country footprint + US onshore capacity | Revenue €2.096 billion, EBITDA margin 38.4%, order book €27.3 billion (~13x revenue) | Largest structural beneficiary of the Russian ban in its segment, industry-best assets; Germany reportedly planning a ~€4 billion buyout of the German stake—sovereignization in progress |
| Orano (unlisted, France ~90%) | 11.0% global; GBII expanding to 10 MSWU; US Ike received $900 million from DOE | Revenue €5.14 billion, EBITDA margin 26.9%, order book €34.4 billion | Fully integrated national champion, aggressive expansion but weaker return discipline than commercial players |
| Centrus Energy (NYSE: LEU) | Non-capacity player: resale of Russian-sourced LEU (TENEX through 2028) + the only operating HALEU plant in the US | Revenue $449 million, gross margin 26.2%, order book $3.8 billion; market cap ~$2.1 billion (2026-11-13) | The "biggest beneficiary of the Russian ban" deserves a discount: current gross profit mostly comes from exempted Russian-supply resale; the real narrative is the post-2029 HALEU commercialization option; the stock, -69% from its peak, has given back most gains |
| TENEX/Rosatom (uninvestable) | #1 global capacity at 42.8%, cheapest cost curve (0.10% tails design) | State-owned, not disclosed | The ghost player of the landscape: the speed of its expulsion from the West (not its capacity) is the true variable of the Western upcycle |
| CNNC (unlisted) | Estimated 20.3% global, 13.8→18.2 MSWU, fully self-sufficient | Not disclosed separately | The third pole: stays out of Western markets; in the 2030s will squeeze Russia's Asian hinterland and depress the global equilibrium price |
| Cameco (NYSE: CCJ) | Uranium mining leader + Port Hope conversion + 49% of GLE (signed in 2026-09 for 100% exclusive offtake of future GLE production) | Revenue C$3.48 billion, gross margin 27.9%; market cap ~$30.8 billion | Enrichment exposure is a free option; mining is the core business; PE ~73x shows valuation is almost entirely a bet on uranium prices |
| Silex Systems (ASX: SLX) | 51% ownership of GLE laser technology; Paducah FEIS cleared, licensing targeted for early 2027 | Revenue A$13.71 million (non-nuclear core business), net loss ~A$27 million; cash A$81 million+ | A pure binary option: if the laser method is validated, the cost curve is rewritten; if it fails, value goes to zero; -65% in 2026 shows the market is withdrawing optimistic pricing |
No corresponding A-share sector index; observe via three tradable proxies (2026-11-13): Centrus PE(TTM) ~30.8x, stock at the ~10th percentile of its 52-week range ($89–338); Cameco PE ~73x / PB ~6x, stock at the ~4th percentile of its 52-week range; Silex loss-making with no PE, at the ~2nd percentile of its range. Interpretation: the 2025 "nuclear power + enrichment" theme was over-priced; the deep 2026 correction has digested most of the theme premium, but absolute levels remain above the pre-2024 norm; sector fundamentals (order books, realized long-term contract prices) have not weakened—the combination of "upcycle × bottom stock prices" means expectations-side risk has been largely released, with residual risk concentrated in post-2028 capacity additions.
United States: The Prohibiting Russian Uranium Imports Act (signed 2024-05-13) bans imports of Russian-produced LEU from 2024-08-11, with waiver authority through end-2027; from 2028-01-01 a full ban applies, sunsetting 2040-12-31. Waivers actually granted: only Centrus has publicly confirmed three (covering 2024–2027 deliveries)—DOE paused then still approved, indicating that extensions are one of the politically default paths. The ADVANCE Act (2024-07) accelerates NRC licensing and legislatively bans Russian/Chinese-made fuel for US advanced reactors. IRA funding disbursement: DOE issued $2.728 billion in ten-year task orders on 2026-01-05 (Centrus $900 million HALEU, General Matter $900 million HALEU, Orano $900 million LEU, GLE $28 million). Russia: Government Resolution No. 1544 of 2024-11-14 imposed a temporary ban on enriched uranium exports to the US (except one-off licenses)—the US and Russia are locked out in both directions, leaving the West only waivers and one-off licenses to keep supplies flowing. EU: As of the 19th sanctions package (2025-10), civil nuclear has not been included—the EU's decoupling from Russia is a soft constraint, and Russian supply can long remain a marginal supplier; this is the largest institutional valve suppressing the magnitude of Western price increases. China: Lanzhou/Hanzhong CEP6 expansion (1.5–2.0 MSWU/yr each), with capacity politically staying out of the West. Net direction: Short term (through 2028), the net policy effect tightens Western supply, bullish for Western suppliers and prices; medium term (2029–2032), subsidized expansion plus a potential armistice thawing constitute concentrated downside price risk; the US, due to its statutory ban (through 2040), has far less exposure to Russian supply returning than Europe.
Bulls: The legal text is explicit, Congress has legislated, and all DOE-subsidized capacity is anchored to the "replace Russian supply" narrative—extension would require the administration to openly contradict itself; without extension, the 3.28 MSWU/yr Russian supply gap lands hard, driving a second spot price spike. Bears: DOE paused and then still approved Centrus's third waiver in 2025—extension is the default path; the EU never imposed an embargo at all, with 22.55% Russian supply still being delivered; under an armistice scenario, returning Russian supply could instantly narrow the nominal gap by about a third. Indicators to track: DOE waiver approvals, renewal of Russia's Resolution 1544, UxC newly signed contract prices.
Bulls: The realized price of $108.70 is still 23.6% below the 2013 peak; repricing takes 3–5 years; order books are locked into the 2030s, so spot weakness ≠ incumbent profit decline (when spot bottomed at $60 in 2016, realized prices were still $109.54 in 2019). Bears: The lag is double-edged—realized prices peak in 2030–2032 exactly when DOE's three plants + Urenco's +4.6 MSWU + GLE are deployed in concentration (2032 committed capacity vs. demand shows a nominal 34% surplus); utilities are clawing back underfeeding benefits; the 2010–16 template (spot 160→60, realized 142→$99.51) could repeat. Indicators to track: UxC annual contract terms survey (share of tails revenue-sharing), whether spot closes below $180 for two consecutive quarters, average prices of newly signed long-term contracts.
Bulls: Centrifuge barriers remain high; the laser method is unproven with no output before 2030. Bears: GLE's progress keeps beating expectations (FEIS cleared 2026-10-28, licensing targeted for early 2027, Cameco's 100% offtake locks in sales, 550,000 tonnes of US tails as feedstock)—the triple "cheap feedstock + new technology + offtake" materializes in concentration in 2030–2032; DOE is using taxpayer money to push the incentive-price floor below $85–100, systematically revising up 2030s supply elasticity. Indicators to track: whether GLE files FID/begins construction within 12 months of obtaining its license in early 2027, the Ike review progress, loading timing of first HALEU reactors (Natrium/Xe-100/Oklo).
| Scenario | Probability | Narrative | SWU Price Implications |
|---|---|---|---|
| Bear | 30% | Waiver extension/armistice thawing by end-2027, Russian supply returns at 3–4 MSWU; overfeeding + inventory releases; GLE and DOE capacity proceed on schedule | Spot falls back to $120–160; realized prices peak after 2029, opening a repeat of the 2010–16 template |
| Base | 50% | Waivers not extended but implemented with transition (one-off licenses/inventory buffers); new capacity ramps gradually 2028–2032 | Spot oscillates at high levels of $170–230 (center ~$200); realized prices rise to $130–145, incumbents gain volume and price before 2029 |
| Bull | 20% | Hard exit confirmed in Jan 2028 + panic buying during the policy vacuum + delayed expansions + earlier-than-expected HALEU/AI demand | Spot $240–300+; new long-term contract base prices $180–220 |
| Date/Window | Event | Directional Impact | Related Controversy |
|---|---|---|---|
| 2027Q1 | GLE Paducah NRC licensing decision | Supply elasticity revised up / laser option monetized | D3 |
| Around 2027-04 | Orano Ike NRC review milestone (reportedly delayed) | Greenfield schedule risk | D2 |
| 1H 2027 | Urenco Almelo Phase 1 startup | Gap narrows slightly | D2 |
| 2027-07/08 | EIA annual Uranium Marketing Annual Report (2026 realized prices) | Repricing slope validation | D2 |
| End of 2027 | US waiver authority expires | The decisive battleground | D1 |
| 2028-01-01 | US full ban on Russian LEU takes effect | Hard exit of Russian supply / policy reversals | D1 |
| 1H 2028 | GBII first module startup; Crane/Duane Arnold restarts | Supply + demand both land | D2 |
| 2029 | Centrus 12-tonne/yr HALEU capacity; TENEX contracts expire | HALEU option / supply cutoff node | D1/D3 |
| 2030 | GLE Paducah startup target | Supply elasticity determines depth of surplus | D3 |
Debunking the value trap logic: a bullish cycle ≠ worth buying. Silex in the lower right is the classic high-cycle × low-realization play—enrichment price gains amplify GLE option value, but the company is currently loss-making and its technology is commercially unproven; it is a binary option for position-sizing purposes, not a core allocation. Russian-supply-dependent channels in the lower left (exposure relying on the TENEX distribution structure) lose both cycle and returns in a 2028 cutoff scenario. Western enrichment overall and Urenco sit in the upper-right "core allocation" zone, but both Urenco and Orano are unlisted, so public markets can only gain exposure via proxies; Centrus sits near the lower edge of the upper-right—a high policy-beta name where the HALEU monopoly option coexists with Russian supply cutoff risk.
Beneficiaries (base case):
Avoid: ① channel-type exposure dependent on Russian-supply resale (TENEX distribution structures without waiver protection—double kill at a 2028 cutoff); ② pure HALEU-narrative small caps with no NRC license and no DOE contract; ③ high-cost new capacity exposure bought high against a $200 spot anchor during the post-2028 supply deployment period.
| Scenario | Biggest Winners | Biggest Losers | One-Line Logic |
|---|---|---|---|
| Bear (30%) | Cameco (mining long-term contracts + GLE option buffer); Urenco (unlisted, order book protection) | Centrus (double kill: Russian supply cutoff + HALEU delay); Silex (worse validation environment) | Under policy reversal, channels and options die first; cash cows survive on contracts |
| Base (50%) | Centrus, Cameco; at the sector level, Urenco/Orano gain volume and price | Pure spot-exposure names; Russian-supply-dependent channels | Realized price catch-up + HALEU monetization; order books dominate |
| Bull (20%) | Centrus (double hit: Russian exit + HALEU); Silex (option value re-rating); Cameco (overfeeding lifts uranium prices) | Russian-supply-dependent channels (lose both waivers and re-export); utilities facing soaring procurement costs anchored to spot | The gap lands hard; option-like names show the greatest elasticity |
① Policy reversal (waiver extension/armistice thawing) rapidly narrows the institutional gap—the single biggest vulnerability of this thesis; ② concentrated supply deployment 2029–2032 plus a utilities counterattack on contract terms, repeating the 2010–16 cycle; ③ successful commercialization of GLE's laser method depressing the long-term cost curve and incumbents' barrier value; ④ state-owned shareholders expanding capacity on energy-security rather than return-oriented logic, depressing the sector's long-term ROIC; ⑤ collective delays of SMR/HALEU first reactors zeroing out the new-track premium; ⑥ deepening overfeeding on the demand side (tails→0.30%) compressing nominal SWU demand by 15%, shifting tightness to mining while enrichment volume and price both weaken.
Data & Definitions: Capacity/shares are WNA nominal capacity figures (2025); Western segment supply-demand is a synthesis of Energy Solutions Intelligence SC-244 and this report; prices: spot is UxC node values as cited by WNA (2026-06-30 is the latest first-hand data), realized prices are from the EIA annual report (2025 report released 2026-07-29); EU deliveries are from the Euratom Supply Agency annual report. All key figures have been arithmetically verified; "not obtained" is marked where applicable. This report does not constitute investment advice.